Idorsia Ltd

🇨🇭Switzerland
Ownership
Subsidiary
Employees
-
Market Cap
$464M
Website
http://www.idorsia.com
Clinical Trials
Related News

A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

First Posted Date
2016-10-12
Last Posted Date
2018-07-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
14
Registration Number
NCT02930655
Locations
🇩🇪

Investigator Site, Würzburg, Germany

A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

First Posted Date
2016-09-29
Last Posted Date
2018-07-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
40
Registration Number
NCT02919319
Locations
🇳🇱

Investigator Site, Leiden, Netherlands

A Study to Evaluate Cenerimod in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Cenerimod
First Posted Date
2016-09-26
Last Posted Date
2018-07-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
6
Registration Number
NCT02914223
Locations
🇳🇱

PRA Health Science, Groningen, Netherlands

A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

Phase 1
Terminated
Conditions
Healthy Subjects
Interventions
Drug: AC-084
Drug: Placebo
First Posted Date
2016-09-19
Last Posted Date
2018-07-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
56
Registration Number
NCT02905253
Locations
🇬🇧

Covance Clinical Research Unit, Leeds, United Kingdom

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Midalozam
Drug: Aprocitentan
First Posted Date
2016-07-22
Last Posted Date
2022-11-29
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
20
Registration Number
NCT02841761
Locations
🇺🇸

Investigator Site, Newark, New Jersey, United States

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Phase 2
Completed
Conditions
Insomnia Disorder
Interventions
Drug: ACT-541468
Drug: Placebo
First Posted Date
2016-07-22
Last Posted Date
2020-04-24
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
58
Registration Number
NCT02841709
Locations
🇩🇪

Investigator Site, Schwerin, Germany

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

First Posted Date
2016-07-20
Last Posted Date
2020-04-13
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
360
Registration Number
NCT02839200
Locations
🇸🇪

Investigator Site, Örebro, Sweden

First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: AC-083
Drug: Placebo
First Posted Date
2016-03-25
Last Posted Date
2018-07-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
72
Registration Number
NCT02719197
Locations
🇩🇪

Investigator Site, Berlin, Germany

Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Other: Placebo
Drug: Aprocitentan
First Posted Date
2016-03-15
Last Posted Date
2022-11-29
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
24
Registration Number
NCT02708004
Locations
🇨🇭

Investigator Site Lausanne, Lausanne, Switzerland

First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: AC-082
Drug: Placebo
First Posted Date
2016-03-09
Last Posted Date
2018-07-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
128
Registration Number
NCT02702648
Locations
🇩🇪

Investigator Site, Berlin, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy